© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to April
potent MAT2A inhibitor in vivo tool
efficacy in MTAP-mut. xenograft (50 mpk SC)
from fragment-based DD (frag. merging)
J. Med. Chem., Apr. 26, 2021
AstraZeneca, Cambridge, UK
The AstraZeneca MAT2a allosteric inhibitor, compound 28, is a remarkably potent (25 nM in cells) in vivo tool compound generated from merging of two weak fragments (Kd = 250 μM…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.